March 2008

Good News for Anti-VEGF Therapy

Robert L. Avery, MD, and Allen C. Ho, MD

Medical Update

David Boyer, MD

Ophthalmologists Remember Judah Folkman, MD

1933-2008

New Innovations in AMD Therapy May Be Promising

Samir Patel, MD

Navigating Contract Negotiation

David Eichenbaum, MD

Retina Comes of Age in the ASC Setting

The time has come to integrate retinal procedures and surgical efficiencies.

Pravin U. Dugel, MD

Collaborative Retina in Latin America: How Did We Get Here?

Fernando Arevalo, MD, FACS

Combined 25/20-gauge Vitreoretinal Surgery: A New 25/20-gauge Plug

Ronald C. Gentile, MD

Mechanisms Behind Disease: DME

Current knowledge of the pathophysiology and pathobiochemistry guides treatment

Albert J. Augustin, MD, and Stanislao Rizzo, MD

Transconjunctival 25-gauge Surgery for Diabetic Traction Retinal Detachment

Results with sutureless technique compare well with 20-gauge.

John O. Mason III, MD

Intravitreal Bevacizumab in the Surgical Treatment of Proliferative Diabetic Retinopathy

Given at the time of surgery, the anti-VEGF agent reduces intraoperative and postoperative bleeding.

Robert L. Avery, MD

Avoid Blind Spots in Surgery While Utilizing Less Energy

Principals from the "green" movement are applied to endoillumination.

Michael Bennett, MD, and Dante Pieramici, MD

Biplanar 5°/30° Insertion Technique

The one-step technique, carefully executed, ensures watertight 23-gauge wound closure.

John S. Pollack, MD

RAD for Central Retinal Vein Occlusion

Novel venous circulation is achieved via creation of multiple venous anastomotic sites.

Calvin Grant, MD

Retinal Detachment Laser Prophylaxis

Ora secunda cerclage (OSC): Creating a second ora.

Robert Morris, MD; C. Douglas Witherspoon, MD; Ferenc Kuhn, MD, PhD; and Mathew Sapp, MD

Pegaptanib Treatment for CRVO

Significant improvement was seen on OCT among patients with macular edema following CRVO.

Karl G. Csaky, MD, PhD

MARINA and ANCHOR: An Overview of the Safety Data

Combined 2-year analysis increases confidence in ranibizumab.

Carl Regillo, MD

Rate of Endophthalmitis After Anti-VEGF Intravitreal Injection

The rate of endophthalmitis was low in a series of almost 20,000 intravitreal injections of anti-VEGF agents.

Andrew A. Moshfeghi, MD

Case Report

Retinal vasoproliferative tumor with associated cystoid macular edema treated with cryotherapy and intravitreal triamcinolone.

Carlos Bianciotto, MD, and Carol L. Shields, MD

CONFERENCE CALENDAR

5 Questions With David W. Parke II, MD

David W. Parke II, MD, was recently named President of the American Academy of Ophthalmology.

David W. Parke II, MD